# SANTA CRUZ BIOTECHNOLOGY, INC.

# PI 3-kinase p110δ siRNA (h): sc-39131



#### -----

### BACKGROUND

Phosphatidylinositol 3-kinase (PI 3-kinase) is composed of p85 and p110 subunits. p85 lacks PI 3-kinase activity and acts as an adapter, coupling p110 to activated protein tyrosine kinase. Two forms of p85 have been described (p85 $\alpha$  and p85 $\beta$ ), each possessing one SH3 and two SH2 domains. Various p110 forms have been identified. p110 $\alpha$  and p110 $\beta$  interact with p85 $\alpha$ , and p110 $\alpha$  has also been shown to interact with p85 $\beta$  *in vitro*. It has been shown to bind p85 $\alpha$  and  $\beta$ , but it apparently does not phosphorylate these subunits. p110 $\delta$  has the capacity to autophosphorylate and results in the nearly complete inactivation of the lipid kinase activity. Interestingly, p110 $\gamma$  does not interact with the p85 subunits and has been shown to be activated by  $\alpha$  and  $\beta\gamma$  heterotrimeric G proteins. Two p110 $\delta$  isoforms have been identified and are widely expressed. Isoform 1 is expressed predominantly in leukocytes while isoform 2 is expressed in normal thymus, lung and spleen tissues.

## REFERENCES

- Skolnik, E.Y., et al. 1991. Cloning of PI 3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65: 83-90.
- Otsu, M., et al. 1991. Characterization of two 85 kDa proteins that associate with receptor tyrosine kinases, middle-T/pp60-src complexes and PI 3-kinase. Cell 65: 91-104.
- 3. Hiles, I.D., et al. 1992. Phosphatidylinositol 3-kinase: structure and expression of the 110 kDa catalytic subunit. Cell 70: 419-429.
- Hu, P., et al. 1993. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell. Biol. 13: 7677-7688.
- Stoyanov, B., et al. 1995. Cloning and characterization of a G proteinactivated human phosphoinositide-3 kinase. Science 269: 690-693.

#### CHROMOSOMAL LOCATION

Genetic locus: PIK3CD (human) mapping to 1p36.22.

#### PRODUCT

PI 3-kinase p110 $\delta$  siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see PI 3-kinase p110 $\delta$  shRNA Plasmid (h): sc-39131-SH and PI 3-kinase p110 $\delta$  shRNA (h) Lentiviral Particles: sc-39131-V as alternate gene silencing products.

### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

#### APPLICATIONS

PI 3-kinase p110 $\delta$  siRNA (h) is recommended for the inhibition of PI 3-kinase p110 $\delta$  expression in human cells.

### SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10  $\mu$ M in 66  $\mu$ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

#### **GENE EXPRESSION MONITORING**

PI 3-kinase p110 $\delta$  (A-8): sc-55589 is recommended as a control antibody for monitoring of PI 3-kinase p110 $\delta$  gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>™</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

#### **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor PI 3-kinase p1108 gene expression knockdown using RT-PCR Primer: PI 3-kinase p1108 (h)-PR: sc-39131-PR (20  $\mu$ l, 518 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### SELECT PRODUCT CITATIONS

- Fransson, S., et al. 2012. p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors. Oncogene 31: 3277-3286.
- Liu, G., et al. 2013. MiR-27a regulates apoptosis in nucleus pulposus cells by targeting PI3K. PLoS ONE 8: e75251.
- Zhou, T., et al. 2018. Runt-related transcription factor 1 (RUNX1) promotes TGF-β-induced renal tubular epithelial-to-mesenchymal transition (EMT) and renal fibrosis through the PI3K subunit p1108. EBioMedicine 31: 217-225.
- Che, N., et al. 2021. Adiponectin enhances B-cell proliferation and differentiation via activation of Akt1/STAT3 and exacerbates collagen-induced arthritis. Front. Immunol. 12: 626310.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.